Why Is Pediatrix Medical Group (MD) Down 1.7% Since Last Earnings Report?

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.

GlobeNewsWire • Jun 4, 2026

Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology.

Business Wire • Jun 3, 2026

HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup

NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Riley J. Williams III, MD, as Venue Medical Officer (VMO) for the 2026 World Cup. The New York / New Jersey area will host matches, including the final, taking place in East Rutherford, New Jersey at MetLife Stadium. In this role, Dr. Williams, Chief of the HSS Sports Medicine Institute, Medical D.

Business Wire • Jun 3, 2026

Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • May 21, 2026

Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the architect of the Locksmith® platform for systematically identifying new therapeutic opportunities from synergistic drug combinations, today announced the appointment of Mandeep Kaur, MD, MS, as Chief Medical Officer. Dr. Kaur will lead Passkey's clinical and medical strategy as it advances a series of Locksmith-identified drug combinations into clinical studies across multiple therapeutic areas. Dr. Kaur most recently served as Senior.

Business Wire • May 19, 2026

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vista.

Business Wire • May 19, 2026

Here's Why You Should Add Pediatrix Medical to Your Portfolio Now

MD gains from stronger cash collections, payer mix and acquisitions, while telehealth expansion and buybacks support growth.

Zacks Investment Research • May 15, 2026

Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • May 14, 2026

Pediatrix Medical Group Q1 Earnings Call Highlights

Pediatrix Medical Group NYSE: MD reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported by higher pricing, improved collections and continued strength in payer mix despite modest volume declines across its service lines.

MarketBeat • May 11, 2026